Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of “Buy” from Analysts

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has earned an average rating of “Buy” from the ten analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $20.89.

Several equities research analysts have weighed in on YMAB shares. Wedbush restated an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. Oppenheimer initiated coverage on shares of Y-mAbs Therapeutics in a research note on Monday, November 18th. They set an “outperform” rating and a $23.00 target price on the stock. Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics in a research note on Thursday, December 5th. They issued a “buy” rating and a $17.00 price target for the company. HC Wainwright reiterated a “buy” rating on shares of Y-mAbs Therapeutics in a report on Wednesday, December 11th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price objective on shares of Y-mAbs Therapeutics in a report on Monday, September 9th.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Hedge funds have recently made changes to their positions in the company. Squarepoint Ops LLC grew its position in shares of Y-mAbs Therapeutics by 143.4% during the second quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock worth $1,527,000 after acquiring an additional 74,452 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Y-mAbs Therapeutics during the 3rd quarter worth $178,000. Intech Investment Management LLC purchased a new position in Y-mAbs Therapeutics during the 3rd quarter worth $133,000. Caligan Partners LP increased its stake in Y-mAbs Therapeutics by 105.3% in the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock valued at $15,718,000 after purchasing an additional 613,175 shares during the period. Finally, Principal Financial Group Inc. purchased a new stake in shares of Y-mAbs Therapeutics in the third quarter valued at about $267,000. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Stock Down 3.5 %

Shares of YMAB opened at $9.43 on Monday. The company has a market cap of $422.37 million, a P/E ratio of -17.46 and a beta of 0.61. Y-mAbs Therapeutics has a fifty-two week low of $6.09 and a fifty-two week high of $20.90. The firm’s 50 day moving average price is $12.87 and its 200 day moving average price is $12.68.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The company had revenue of $18.46 million for the quarter, compared to analysts’ expectations of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period in the prior year, the company posted ($0.18) EPS. Research analysts forecast that Y-mAbs Therapeutics will post -0.66 earnings per share for the current year.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.